Literature DB >> 1512551

Clostridium perfringens enterotoxin is a superantigen reactive with human T cell receptors V beta 6.9 and V beta 22.

P Bowness1, P A Moss, H Tranter, J I Bell, A J McMichael.   

Abstract

Candidate superantigens were screened for their ability to induce lysis of human histocompatibility leukocyte antigen class II-positive targets by human CD8+ influenza-specific cytotoxic T cell (CTL) lines. Clostridium perfringens enterotoxin (CPET) induced major histocompatibility complex unrestricted killing by some but not all CTL lines. Using "anchored" polymerase chain reactions, CPET was shown to selectively stimulate peripheral blood lymphocytes bearing T cell receptor V beta 6.9 and V beta 22 in five healthy donors. V beta 24, V beta 21, V beta 18, V beta 5, and V beta 6.1-5 appeared to be weakly stimulated. Antigen processing was not required for CPET to induce proliferation. Like the staphylococcal enterotoxins, CPET is a major cause of food poisoning. These data suggest that superantigenic and enterotoxigenic properties may be closely linked.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512551      PMCID: PMC2119363          DOI: 10.1084/jem.176.3.893

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Variation in human T cell receptor V beta and J beta repertoire: analysis using anchor polymerase chain reaction.

Authors:  W M Rosenberg; P A Moss; J I Bell
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

2.  Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor.

Authors:  M Dohlsten; G Hedlund; S Segren; P A Lando; T Herrmann; A P Kelly; T Kalland
Journal:  Eur J Immunol       Date:  1991-05       Impact factor: 5.532

3.  Studies on the human T cell receptor alpha/beta variable region genes. II. Identification of four additional V beta subfamilies.

Authors:  L Ferradini; S Roman-Roman; J Azocar; H Michalaki; F Triebel; T Hercend
Journal:  Eur J Immunol       Date:  1991-04       Impact factor: 5.532

4.  Specific diagnosis of foodborne disease.

Authors:  M A Horwitz
Journal:  Gastroenterology       Date:  1977-08       Impact factor: 22.682

5.  Accessory cell-independent stimulation of human T cells by streptococcal M protein superantigen.

Authors:  M Kotb; G Majumdar; M Tomai; E H Beachey
Journal:  J Immunol       Date:  1990-09-01       Impact factor: 5.422

Review 6.  Consequences of self and foreign superantigen interaction with specific V beta elements of the murine TCR alpha beta.

Authors:  J W Kappler; A Pullen; J Callahan; Y Choi; A Herman; J White; W Potts; E Wakeland; P Marrack
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1989

7.  Intestinal Clostridium perfringens in rheumatoid arthritis and other collagen diseases.

Authors:  B Olhagen; I Månsson
Journal:  Acta Med Scand       Date:  1968-11

8.  Sequences and repertoire of the human T cell receptor alpha and beta chain variable region genes in thymocytes.

Authors:  N Kimura; B Toyonaga; Y Yoshikai; R P Du; T W Mak
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

9.  Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2.

Authors:  F Gotch; J Rothbard; K Howland; A Townsend; A McMichael
Journal:  Nature       Date:  1987 Apr 30-May 6       Impact factor: 49.962

10.  Selective expansion of T cells expressing V beta 2 in toxic shock syndrome.

Authors:  Y Choi; J A Lafferty; J R Clements; J K Todd; E W Gelfand; J Kappler; P Marrack; B L Kotzin
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  11 in total

1.  Staphylococcal enterotoxin B primes cytokine secretion and lytic activity in response to native bacterial antigens.

Authors:  K M Mason; T D Dryden; N J Bigley; P S Fink
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

Review 2.  Evidence for a superantigen in the pathogenesis of tuberculosis.

Authors:  J D Ohmen; R L Modlin
Journal:  Springer Semin Immunopathol       Date:  1996

Review 3.  Superantigens in insulin-dependent diabetes mellitus.

Authors:  P Luppi; M Trucco
Journal:  Springer Semin Immunopathol       Date:  1996

Review 4.  Bacterial pyrogenic exotoxins as superantigens.

Authors:  M Kotb
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

5.  Clostridium perfringens enterotoxin lacks superantigenic activity but induces an interleukin-6 response from human peripheral blood mononuclear cells.

Authors:  T Krakauer; B Fleischer; D L Stevens; B A McClane; B G Stiles
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Toxicity of staphylococcal enterotoxins potentiated by lipopolysaccharide: major histocompatibility complex class II molecule dependency and cytokine release.

Authors:  B G Stiles; S Bavari; T Krakauer; R G Ulrich
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

7.  Staphylococcal enterotoxin type A internal deletion mutants: serological activity and induction of T-cell proliferation.

Authors:  T O Harris; W O Hufnagle; M J Betley
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

8.  Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo.

Authors:  C Michie; A Scott; J Cheesbrough; P Beverley; G Pasvol
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

Review 9.  Superantigens and pseudosuperantigens of gram-positive cocci.

Authors:  B Fleischer; D Gerlach; A Fuhrmann; K H Schmidt
Journal:  Med Microbiol Immunol       Date:  1995-05       Impact factor: 3.402

Review 10.  Staphylococcal and streptococcal superantigen exotoxins.

Authors:  Adam R Spaulding; Wilmara Salgado-Pabón; Petra L Kohler; Alexander R Horswill; Donald Y M Leung; Patrick M Schlievert
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.